Eli Lilly (LLY -0.3%) announces new data from a Phase 2b clinical trial
evaluating lebrikizumab in patients with moderate-to-severe atopic
dermatitis (AD). The results were virtually presented at the American
Academy of Dermatology Annual Meeting. Key findings:
Itch by day 2 improved to week 16.
Sleep by the first on-treatment assessment at week 1 which improved to week 16.
Disease severity improved by the first on-treatment assessment at week 16.
Quality of life measures improved.
Five Phase 3 studies are underway.
Lebrikizumab is an injectable humanized monoclonal
antibody that binds to (inhibits) a pro-inflammatory protein called
interleukin-13 (IL-13).
Lilly obtained the rights to the candidate via its $1.1B acquisition of Dermira in February.
https://seekingalpha.com/news/3582761-lillys-lebrikizumab-shows-encouraging-action-in-dermatitis-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.